Trevi Therapeutics Shares Surge 13% as Biopharma Investors Cheer Cough Drug Data at London Conference
Trevi Therapeutics shares rose 13.10% to $19.64 after the company presented clinical data on Haduvio (nalbuphine extended-release) for chronic cough at the European Respiratory Society Cough Conference in London. Trevi said results show a statistically significant cough-frequency reduction across IPF-related and refractory chronic cough. Analysts cited a $21.10 average target; Trevi also reported a June $162 million net offering.
How this was made
The 30-second read
Why it matters
The article attributes a same-day 13.1% stock jump to investor focus on Haduvio clinical trial presentations at the European Respiratory Society’s Cough Conference in London, reiterating the company’s claim of statistically significant cough-frequency reduction across populations.
Market read
Traders can treat the London conference as a near-term sentiment catalyst for TRVI, while the Aug 6 earnings date is the next scheduled opportunity for incremental Phase 3 progress details.
What to watch
Index removal (Russell reshuffle) could reintroduce technical selling pressure; also, the article does not provide new quantitative endpoints or safety details from the London presentations, so traders may be over-weighting qualitative claims.
Background
Trevi is a clinical-stage biopharma developing Haduvio (nalbuphine extended-release) for chronic cough associated with IPF and non-IPF interstitial lung disease, plus refractory chronic cough.
Ticker impact
TRVI shares jumped 13.1% after London conference presentations highlighted new Haduvio chronic-cough trial results and market positioning.
Near-term upside bias while investors digest the London data narrative; risk of mean reversion if next catalysts fail to add incremental efficacy or regulatory clarity.
The article ties the same-day rally to conference attention and reiterates claims of statistically significant cough-frequency reduction across IPF and refractory chronic cough, while also flagging that Haduvio is still investigational and the next major catalyst is the Aug 6 earnings update.
Market effects
Reinforces investor appetite for late-stage respiratory therapeutics and opioid-receptor pathway cough programs, potentially lifting sentiment for similar clinical-stage biopharma names.
Limited direct regional spillover; the catalyst is a US-listed biotech’s European conference presence.
Moderate, as chronic cough in interstitial lung disease is a global unmet-need theme, but the article is primarily company-specific.
Counterpoint
The rally may be driven more by narrative and conference visibility than by truly incremental, decision-grade efficacy or safety data versus what the market already expects from CORAL and prior accepted presentations.
Key entities
- companyTrevi Therapeutics
US-listed clinical-stage biopharma whose stock rose 13.1% on investor attention to Haduvio cough trial presentations.
- productHaduvio
Oral extended-release nalbuphine investigational therapy for chronic cough in IPF and non-IPF interstitial lung disease and refractory chronic cough.
- eventEuropean Respiratory Society Cough Conference
London conference where Trevi executives presented Haduvio clinical trial results.
- clinical_programCORAL trial
Phase 2b trial evaluating nalbuphine extended-release in IPF-related chronic cough, with analyses accepted for oral presentation earlier in 2026.
